Sanofi will work with the Biomedical Advanced Research and Development Authority to retrofit vaccine manufacturing facilities in Swiftwater, Pa. The effort will double Sanofi’s capacity to manufacture a recombinant protein-based flu shot.
The agreement gives HHS access to the drugmaker’s vaccine production capacity for up to 25 years, which translates into nearly 1 million flu shot doses for use during a pandemic.
Sanofi is the only drugmaker licensed to manufacture a recombinant flu shot in the U.S., which is much quicker to produce than traditional egg-based vaccines.
More articles on clinical leadership & infection control:
Mount Sinai’s ED is a ‘war zone,’ nurse says
Dallas children’s hospital relocates 28 patients after mold discovery
Police raid Georgia psych hospital over abuse allegations
